Protein predicts post-RP cancer recurrence, death

Men who had high levels of the activated Stat5 protein in their prostate cancer after a radical prostatectomy were more likely to have a recurrence or die from the disease compared to men who had little to no presence of the growth protein, according to a recent report.

Related Videos

Related Content

Advertisement

January 14th 2025

Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial

Hannah Clarke

“In this phase 2 study, an image-guided adaptive strategy enabled radiotherapy dose escalation to over 86% of patients’ bladder tumors without significant increase in toxicity,” wrote the authors.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 13th 2025

Hackensack University Medical Center Launches Educational Website for People with Kidney Cancer

The Kidney Cancer Resource Center is a collaborative effort by Hackensack Meridian Health’s leading experts in the field of renal cell carcinoma.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 13th 2025

Enrollment goal met in trial of Urocross Expander Implant for BPH-related LUTS

Hannah Clarke

The Expander-2 trial is intended to provide data that will support submission of the device for regulatory approval.

January 11th 2025

The economics of bladder cancer in the US: Increasing costs and unsustainable patterns

Michael S. Cookson, MD, MMHC

"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.

Related Content

Advertisement

January 14th 2025

Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial

Hannah Clarke

“In this phase 2 study, an image-guided adaptive strategy enabled radiotherapy dose escalation to over 86% of patients’ bladder tumors without significant increase in toxicity,” wrote the authors.

January 14th 2025

Episode 2 Podcast: Managing Overactive Bladder: From Dual Diagnoses to Geriatric Challenges

Wayne Kuang, MD Steven Maislos, MD

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

January 13th 2025

Hackensack University Medical Center Launches Educational Website for People with Kidney Cancer

The Kidney Cancer Resource Center is a collaborative effort by Hackensack Meridian Health’s leading experts in the field of renal cell carcinoma.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

January 13th 2025

Enrollment goal met in trial of Urocross Expander Implant for BPH-related LUTS

Hannah Clarke

The Expander-2 trial is intended to provide data that will support submission of the device for regulatory approval.

January 11th 2025

The economics of bladder cancer in the US: Increasing costs and unsustainable patterns

Michael S. Cookson, MD, MMHC

"The increasing expenses associated with bladder cancer treatment highlight wider issues regarding the sustainability of health care expenditures in the US," writes Michael S. Cookson, MD, MMHC, FACS.